Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial

Table 2 Radiological parameters

Radiological parameters (n = 79)	Median [range]^a
Total diameter of the target lesions (mm)
At baseline	78.2 [14.7–199.3]
At the first restaging	62 [6.9–179.5]
Mean tumor density (HU)
At baseline	62.8 [23.9–117.3]
At the first restaging	53.5 [6.9–179.5]
Mean healthy liver density (HU)
At baseline	99.2 [27.6–134.8]
At the first restaging	99.8 [39.2–143.9]
TTLD ratio
At baseline	0.62 [0.34–2.06]
At the first restaging	0.54 [0.28–1.14]
RECIST_-15^b
CR/PR	50 (63)
SD	27 (34)
PD	2 (3)
MD Anderson morphologic response^b
Optimal	31 (47)
Suboptimal or no response	35 (53)
Missing	13

TTLD Tumor-to-liver density ratio, RECIST_-15 Response Evaluation Criteria in Solid Tumors using a modified cut-off value of -15%, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease
^aExcept for the RECIST_-15 response and MD Anderson response that are reported as n (%)
^bRecorded at the first restaging

ISSN: 1470-7330